Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CERo Therapeutics Holdings ( (CERO) ) has shared an update.
On January 7, 2026, CERo Therapeutics Holdings published an investor presentation and issued a press release providing a clinical update from its Phase 1 CERTAINT-1 trial of CER-1236 in AML, including a patient with myelodysplastic syndrome/AML. Early data from four treated patients showed robust CER-1236 T cell expansion without any reported cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or other treatment-related adverse events to date, and demonstrated that repeat dosing without lymphodepletion is feasible, with platelet recovery observed in one MDS/AML patient—findings that, if sustained in larger cohorts, could enhance the company’s positioning in the competitive cell therapy landscape for blood cancers.
The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is a biotechnology company developing engineered T cell therapies, including its CER-T cell platform that uses the TIM-4 phagocytic receptor to target tumor cells, with a focus on treating hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Average Trading Volume: 1,895,491
Technical Sentiment Signal: Sell
Current Market Cap: $1.37M
For an in-depth examination of CERO stock, go to TipRanks’ Overview page.